{"id":22811,"date":"2026-08-13T10:57:15","date_gmt":"2026-08-13T08:57:15","guid":{"rendered":"https:\/\/mic-site.labiux.com\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/"},"modified":"2026-08-13T10:57:15","modified_gmt":"2026-08-13T08:57:15","slug":"litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku","status":"publish","type":"post","link":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/","title":{"rendered":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku"},"content":{"rendered":"<div class=\"wp-block-labiux-legacy-html legacy-content\">\n<p>Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to.<\/p>\n<p>\u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar JAK inhibitoriem saist\u012btie riski, t.i., \u2014 noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), \u013caundab\u012bgi audz\u0113ji, nopietnas infekcijas un v\u0113nu trombembolija (VTE) \u2014 ir attiecin\u0101mi ar\u012b uz Litfulo t\u0101 apstiprin\u0101t\u0101s indik\u0101cijas gad\u012bjum\u0101.<br \/>\n\u2022 Sekojo\u0161i pacienti Litfulo dr\u012bkst lietot tikai tad, ja nav pieejamas piem\u0113rotas terapijas alternat\u012bvas:<br \/>\no 65 gadus veci un vec\u0101ki pacienti;<br \/>\no pacienti, kuriem anamn\u0113z\u0113 ir aterosklerotiska kardiovaskul\u0101ra slim\u012bba vai citi kardiovaskul\u0101r\u0101 riska faktori (piem\u0113ram, kuri sm\u0113\u0137\u0113, vai ir biju\u0161i ilgsto\u0161i sm\u0113\u0137\u0113t\u0101ji);<br \/>\no pacienti ar \u013caundab\u012bgu audz\u0113ju riska faktoriem (piem\u0113ram, pa\u0161reiz\u0113ju \u013caundab\u012bgu audz\u0113ju vai \u013caundab\u012bgu audz\u0113ju anamn\u0113z\u0113).<br \/>\n\u2022 Litfulo ar piesardz\u012bbu j\u0101lieto pacientiem ar\u012b ar citiem augst\u0101k nenor\u0101d\u012btiem VTE riska faktoriem.<br \/>\n\u2022 Visiem pacientiem ieteicama periodiska \u0101das p\u0101rbaude.<\/p>\n<p><strong>S\u012bk\u0101ka inform\u0101cija par dro\u0161uma apsv\u0113rumiem un rekomend\u0101cij\u0101m<\/strong><br \/>\nLitfulo (ritlecitinibs) ir selekt\u012bvs JAK3 un TEC saimes kin\u0101\u017eu inhibitors, kas 2023. gada septembr\u012b tika apstiprin\u0101ts smagas plankumain\u0101s plikgalv\u012bbas (alopecia areata) \u0101rst\u0113\u0161anai pieaugu\u0161ajiem un pusaud\u017eiem no 12 gadu vecuma.<br \/>\n2023. gada febru\u0101r\u012b vesel\u012bbas apr\u016bpes speci\u0101listiem tika izplat\u012bta VVAS par Cibinqo (abrocitinibs), Jyseleca (filgotinibs), Olumiant (baricitinibs), Rinvoq (upadacitinibs) un Xeljanz (tofacitinibs), inform\u0113jot, ka pacientiem ar reimato\u012bdo artr\u012btu (RA), kuriem ir noteikti riska faktori un kuri tiek \u0101rst\u0113ti ar JAK inhibitoriem, bie\u017e\u0101k tiek nov\u0113roti \u013caundab\u012bgi audz\u0113ji, noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), nopietnas infekcijas, venoz\u0101 trombembolija (VTE) un let\u0101li gad\u012bjumi, sal\u012bdzinot ar pacientiem, kuri tiek \u0101rst\u0113ti ar TNF\u03b1 inhibitoriem. \u0160ie riski tika uzskat\u012bti par attiec\u012bgajai z\u0101\u013cu grupai rakstur\u012bgiem efektiem, un tie attiecas uz vis\u0101m apstiprin\u0101taj\u0101m JAK inhibitoru lieto\u0161anas indik\u0101cij\u0101m iekais\u012bgu un dermatolo\u0123isku slim\u012bbu gad\u012bjum\u0101. T\u0101d\u0113\u013c tika \u012bstenoti risku mazin\u0101\u0161anas pas\u0101kumi, kas attiecas uz visu attiec\u012bgo z\u0101\u013cu grupu, lai \u0161os riskus mazin\u0101tu.<br \/>\nVeicot EZA regul\u0101ro Litfulo ieguvumu un risku l\u012bdzsvara izv\u0113rt\u0113\u0161anu, kas balst\u012bta uz kl\u012bnisko p\u0113t\u012bjumu un p\u0113cre\u0123istr\u0101cijas datu kopu, un \u0146emot v\u0113r\u0101, ka tr\u016bkst nep\u0101rprotamu datu, kas apliecin\u0101tu, ka selektivit\u0101te attiec\u012bb\u0101 uz JAK3\/TEC nov\u0113r\u0161 \u0161os riskus, tika secin\u0101ts, ka piesardz\u012bbas pas\u0101kumi, kas ieteikti 20. panta proced\u016br\u0101 attiec\u012bb\u0101 uz JAK inhibitoriem hronisku iekais\u012bgu slim\u012bbu \u0101rst\u0113\u0161an\u0101, ir piem\u0113rojami ar\u012b Litfulo gad\u012bjum\u0101. T\u0101d\u0113\u013c ir veikti pas\u0101kumi \u0161o risku mazin\u0101\u0161anai, k\u0101 nor\u0101d\u012bts kopsavilkum\u0101 iepriek\u0161.<br \/>\nLitfulo z\u0101\u013cu inform\u0101cija tiks attiec\u012bgi groz\u012bta. Kopum\u0101 EZA secin\u0101ja, ka Litfulo ieguvumu un risku attiec\u012bba joproj\u0101m ir pozit\u012bva. Atjaunin\u0101to ieteikumu m\u0113r\u0137is ir atbalst\u012bt un stiprin\u0101t risku mazin\u0101\u0161anas pas\u0101kumus.<\/p>\n<p>Avots: ZVA<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to. \u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":12108,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"mic_cinema_image":0,"mic_focus":"","mic_cinema_focus":"","footnotes":"","_labiux_rail":0},"categories":[76,73],"tags":[2882,2883],"mic_flag":[],"class_list":["post-22811","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-jaunakie-raksti","category-medikamentu-zinas","tag-litfulo","tag-ritlecitinibs"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.4 - aioseo.com -->\n\t<meta name=\"description\" content=\"Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to. \u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar JAK inhibitoriem saist\u012btie riski, t.i., \u2014 noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), \u013caundab\u012bgi audz\u0113ji, nopietnas infekcijas un v\u0113nu trombembolija (VTE) \u2014 ir attiecin\u0101mi ar\u012b uz Litfulo\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"admin\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.4\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:description\" content=\"Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to. \u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar JAK inhibitoriem saist\u012btie riski, t.i., \u2014 noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), \u013caundab\u012bgi audz\u0113ji, nopietnas infekcijas un v\u0113nu trombembolija (VTE) \u2014 ir attiecin\u0101mi ar\u012b uz Litfulo\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/\" \/>\n\t\t<meta property=\"og:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/zva_log.jpg\" \/>\n\t\t<meta property=\"og:image:secure_url\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/zva_log.jpg\" \/>\n\t\t<meta property=\"og:image:width\" content=\"660\" \/>\n\t\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-08-13T08:57:15+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-08-13T08:57:15+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to. \u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar JAK inhibitoriem saist\u012btie riski, t.i., \u2014 noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), \u013caundab\u012bgi audz\u0113ji, nopietnas infekcijas un v\u0113nu trombembolija (VTE) \u2014 ir attiecin\u0101mi ar\u012b uz Litfulo\" \/>\n\t\t<meta name=\"twitter:image\" content=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/zva_log.jpg\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/medikamentu-zinas\\\/#listItem\",\"name\":\"Medikamenti\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/medikamentu-zinas\\\/#listItem\",\"position\":2,\"name\":\"Medikamenti\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/medikamentu-zinas\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#listItem\",\"name\":\"Litfulo (ritlecitinib): atjaunin\\u0101ti ieteikumi, lai mazin\\u0101tu \\u013caundab\\u012bgu audz\\u0113ju, noz\\u012bm\\u012bgu nev\\u0113lamu kardiovaskul\\u0101ru notikumu, nopietnu infekciju, v\\u0113nu trombembolijas un mirst\\u012bbas risku\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#listItem\",\"position\":3,\"name\":\"Litfulo (ritlecitinib): atjaunin\\u0101ti ieteikumi, lai mazin\\u0101tu \\u013caundab\\u012bgu audz\\u0113ju, noz\\u012bm\\u012bgu nev\\u0113lamu kardiovaskul\\u0101ru notikumu, nopietnu infekciju, v\\u0113nu trombembolijas un mirst\\u012bbas risku\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/medikamentu-zinas\\\/#listItem\",\"name\":\"Medikamenti\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#newsarticle\",\"name\":\"Litfulo (ritlecitinib): atjaunin\\u0101ti ieteikumi, lai mazin\\u0101tu \\u013caundab\\u012bgu audz\\u0113ju, noz\\u012bm\\u012bgu nev\\u0113lamu kardiovaskul\\u0101ru notikumu, nopietnu infekciju, v\\u0113nu trombembolijas un mirst\\u012bbas risku - Medikamentu Inform\\u0101cijas Centrs\",\"headline\":\"Litfulo (ritlecitinib): atjaunin\\u0101ti ieteikumi, lai mazin\\u0101tu \\u013caundab\\u012bgu audz\\u0113ju, noz\\u012bm\\u012bgu nev\\u0113lamu kardiovaskul\\u0101ru notikumu, nopietnu infekciju, v\\u0113nu trombembolijas un mirst\\u012bbas risku\",\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/zva_log.jpg\",\"width\":660,\"height\":330},\"datePublished\":\"2026-08-13T10:57:15+03:00\",\"dateModified\":\"2026-08-13T10:57:15+03:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#webpage\"},\"articleSection\":\"Jaun\\u0101kie raksti, Medikamenti, Litfulo, ritlecitinibs\",\"dateline\":\"Published on August 13, 2026.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"admin\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#webpage\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/\",\"name\":\"Litfulo (ritlecitinib): atjaunin\\u0101ti ieteikumi, lai mazin\\u0101tu \\u013caundab\\u012bgu audz\\u0113ju, noz\\u012bm\\u012bgu nev\\u0113lamu kardiovaskul\\u0101ru notikumu, nopietnu infekciju, v\\u0113nu trombembolijas un mirst\\u012bbas risku - Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\\u0101\\u013cu a\\u0123ent\\u016bru (EZA) un Latvijas Z\\u0101\\u013cu valsts a\\u0123ent\\u016bru, inform\\u0113 vesel\\u012bbas apr\\u016bpes speci\\u0101listus par turpm\\u0101k min\\u0113to. \\u2022 Pamatojoties uz jaun\\u0101ko pieejamo datu izv\\u0113rt\\u0113jumu, ar JAK inhibitoriem saist\\u012btie riski, t.i., \\u2014 noz\\u012bm\\u012bgi nev\\u0113lami kardiovaskul\\u0101ri notikumi (NNKN), \\u013caundab\\u012bgi audz\\u0113ji, nopietnas infekcijas un v\\u0113nu trombembolija (VTE) \\u2014 ir attiecin\\u0101mi ar\\u012b uz Litfulo\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/admin\\\/#author\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/zva_log.jpg\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#mainImage\",\"width\":660,\"height\":330},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\\\/#mainImage\"},\"datePublished\":\"2026-08-13T10:57:15+03:00\",\"dateModified\":\"2026-08-13T10:57:15+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku - Medikamentu Inform\u0101cijas Centrs","description":"Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to. \u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar JAK inhibitoriem saist\u012btie riski, t.i., \u2014 noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), \u013caundab\u012bgi audz\u0113ji, nopietnas infekcijas un v\u0113nu trombembolija (VTE) \u2014 ir attiecin\u0101mi ar\u012b uz Litfulo","canonical_url":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/farmacija-mic.lv\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/#listItem","name":"Medikamenti"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/#listItem","position":2,"name":"Medikamenti","item":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#listItem","name":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku"},"previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#listItem","position":3,"name":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku","previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/#listItem","name":"Medikamenti"}}]},{"@type":"NewsArticle","@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#newsarticle","name":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku - Medikamentu Inform\u0101cijas Centrs","headline":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku","author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/zva_log.jpg","width":660,"height":330},"datePublished":"2026-08-13T10:57:15+03:00","dateModified":"2026-08-13T10:57:15+03:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#webpage"},"isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#webpage"},"articleSection":"Jaun\u0101kie raksti, Medikamenti, Litfulo, ritlecitinibs","dateline":"Published on August 13, 2026."},{"@type":"Organization","@id":"https:\/\/farmacija-mic.lv\/en\/#organization","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","url":"https:\/\/farmacija-mic.lv\/en\/"},{"@type":"Person","@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author","url":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/","name":"admin","image":{"@type":"ImageObject","@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/be3221a6fac131657111728b4d912a877ec158b123d5db3afef3bd8a59784ece?s=96&d=mm&r=g","width":96,"height":96,"caption":"admin"}},{"@type":"WebPage","@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#webpage","url":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/","name":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku - Medikamentu Inform\u0101cijas Centrs","description":"Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to. \u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar JAK inhibitoriem saist\u012btie riski, t.i., \u2014 noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), \u013caundab\u012bgi audz\u0113ji, nopietnas infekcijas un v\u0113nu trombembolija (VTE) \u2014 ir attiecin\u0101mi ar\u012b uz Litfulo","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/#website"},"breadcrumb":{"@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#breadcrumblist"},"author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"creator":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/admin\/#author"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/zva_log.jpg","@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#mainImage","width":660,"height":330},"primaryImageOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/#mainImage"},"datePublished":"2026-08-13T10:57:15+03:00","dateModified":"2026-08-13T10:57:15+03:00"},{"@type":"WebSite","@id":"https:\/\/farmacija-mic.lv\/en\/#website","url":"https:\/\/farmacija-mic.lv\/en\/","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","inLanguage":"en-US","publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Medikamentu Inform\u0101cijas Centrs","og:type":"article","og:title":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku - Medikamentu Inform\u0101cijas Centrs","og:description":"Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to. \u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar JAK inhibitoriem saist\u012btie riski, t.i., \u2014 noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), \u013caundab\u012bgi audz\u0113ji, nopietnas infekcijas un v\u0113nu trombembolija (VTE) \u2014 ir attiecin\u0101mi ar\u012b uz Litfulo","og:url":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/","og:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/zva_log.jpg","og:image:secure_url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/zva_log.jpg","og:image:width":660,"og:image:height":330,"article:published_time":"2026-08-13T08:57:15+00:00","article:modified_time":"2026-08-13T08:57:15+00:00","twitter:card":"summary_large_image","twitter:title":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku - Medikamentu Inform\u0101cijas Centrs","twitter:description":"Pfizer Europe MA EEIG, vienojoties ar Eiropas Z\u0101\u013cu a\u0123ent\u016bru (EZA) un Latvijas Z\u0101\u013cu valsts a\u0123ent\u016bru, inform\u0113 vesel\u012bbas apr\u016bpes speci\u0101listus par turpm\u0101k min\u0113to. \u2022 Pamatojoties uz jaun\u0101ko pieejamo datu izv\u0113rt\u0113jumu, ar JAK inhibitoriem saist\u012btie riski, t.i., \u2014 noz\u012bm\u012bgi nev\u0113lami kardiovaskul\u0101ri notikumi (NNKN), \u013caundab\u012bgi audz\u0113ji, nopietnas infekcijas un v\u0113nu trombembolija (VTE) \u2014 ir attiecin\u0101mi ar\u012b uz Litfulo","twitter:image":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/zva_log.jpg"},"aioseo_meta_data":{"post_id":"22811","title":null,"description":null,"keywords":null,"keyphrases":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":null,"og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":null,"robots_max_videopreview":null,"robots_max_imagepreview":"large","priority":null,"frequency":null,"local_seo":null,"limit_modified_date":false,"ai":null,"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-10-16 19:50:05","updated":"2026-10-16 19:50:05"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/\" title=\"Medikamenti\">Medikamenti<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tLitfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/farmacija-mic.lv\/en\/"},{"label":"Medikamenti","link":"https:\/\/farmacija-mic.lv\/category\/medikamentu-zinas\/"},{"label":"Litfulo (ritlecitinib): atjaunin\u0101ti ieteikumi, lai mazin\u0101tu \u013caundab\u012bgu audz\u0113ju, noz\u012bm\u012bgu nev\u0113lamu kardiovaskul\u0101ru notikumu, nopietnu infekciju, v\u0113nu trombembolijas un mirst\u012bbas risku","link":"https:\/\/farmacija-mic.lv\/en\/litfulo-ritlecitinib-atjauninati-ieteikumi-lai-mazinatu-laundabigu-audzeju-nozimigu-nevelamu-kardiovaskularu-notikumu-nopietnu-infekciju-venu-trombembolijas-un-mirstibas-risku\/"}],"_links":{"self":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22811","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/comments?post=22811"}],"version-history":[{"count":0,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/22811\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media\/12108"}],"wp:attachment":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media?parent=22811"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/categories?post=22811"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/tags?post=22811"},{"taxonomy":"mic_flag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/mic_flag?post=22811"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}